The pharma chums argument that denying patents to drug companies and eating into their profits will inhibit research investment into future wonder drugs was knocked down easily in the U.S, particular in the case of Gleevec. The acclaimed drug, considered a magic bullet for leukemia, was actually developed jointly by Dr Brian Druker, director of the Oregon and Science University Knight Cancer Institute, in collaboration with . In that sense, it had some public funding.
Druker himself welcomed the Indian Supreme Court
ruling in an interview with the Times of India, but with a caveat: the
price of medications should not be restricted to the extent that it
inhibits future investment in new drugs. At the same time, he also
criticized the pharma majors' predatory pricing and the enormous profits
they made on many blockbuster drugs.